Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease
Crohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) characterized by skip intestinal lesions that can occur in any part of the gastrointestinal tract. Currently, the diagnosis of CD is based on clinical history, physical examination and complementary diagnostic tests. It is ch...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.814839/full |
| _version_ | 1828408254514855936 |
|---|---|
| author | Huanhuan Liu Huanhuan Liu Minmin Xu Qiongzi He Peng Wei Mengying Ke Shijia Liu |
| author_facet | Huanhuan Liu Huanhuan Liu Minmin Xu Qiongzi He Peng Wei Mengying Ke Shijia Liu |
| author_sort | Huanhuan Liu |
| collection | DOAJ |
| description | Crohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) characterized by skip intestinal lesions that can occur in any part of the gastrointestinal tract. Currently, the diagnosis of CD is based on clinical history, physical examination and complementary diagnostic tests. It is challenging for physicians to make a definitive diagnosis. This study aimed to analyze the variation in metabolites in CD serum and identify potential predictive biomarkers of CD diagnosis. We collected serum samples from 316 subjects, including patients with CD and healthy controls (HCs). Serum metabolomics was conducted using liquid chromatography coupled to mass spectrometry. Potential biomarkers were screened and evaluated by univariate and multivariate analyses. A panel of two metabolites (deoxycholic acid and palmitic amide) was identified as a specific biomarker of CD. Receiver operating characteristic analysis (ROC) showed that the panel had a sensitivity of 80.25% with a specificity of 95.54% in discriminating CD patients from healthy controls. The biomarkers identified are increased in CD compared with healthy controls. Our approach successfully identified serum biomarkers associated with CD patients. The potential biomarkers indicated that CD metabolic disturbance might be associated with bile acid biosynthesis, fatty acids and energy metabolism. |
| first_indexed | 2024-12-10T11:37:05Z |
| format | Article |
| id | doaj.art-f916444eaa434b91a901655b69191cba |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-10T11:37:05Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-f916444eaa434b91a901655b69191cba2022-12-22T01:50:24ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-09-01910.3389/fmed.2022.814839814839Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's diseaseHuanhuan Liu0Huanhuan Liu1Minmin Xu2Qiongzi He3Peng Wei4Mengying Ke5Shijia Liu6Department of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaCollege of Pharmacy, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaCollege of Pharmacy, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaCrohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) characterized by skip intestinal lesions that can occur in any part of the gastrointestinal tract. Currently, the diagnosis of CD is based on clinical history, physical examination and complementary diagnostic tests. It is challenging for physicians to make a definitive diagnosis. This study aimed to analyze the variation in metabolites in CD serum and identify potential predictive biomarkers of CD diagnosis. We collected serum samples from 316 subjects, including patients with CD and healthy controls (HCs). Serum metabolomics was conducted using liquid chromatography coupled to mass spectrometry. Potential biomarkers were screened and evaluated by univariate and multivariate analyses. A panel of two metabolites (deoxycholic acid and palmitic amide) was identified as a specific biomarker of CD. Receiver operating characteristic analysis (ROC) showed that the panel had a sensitivity of 80.25% with a specificity of 95.54% in discriminating CD patients from healthy controls. The biomarkers identified are increased in CD compared with healthy controls. Our approach successfully identified serum biomarkers associated with CD patients. The potential biomarkers indicated that CD metabolic disturbance might be associated with bile acid biosynthesis, fatty acids and energy metabolism.https://www.frontiersin.org/articles/10.3389/fmed.2022.814839/fullserum metabolomicsCrohn's diseasebiomarkerLC-MSmetabolite profile |
| spellingShingle | Huanhuan Liu Huanhuan Liu Minmin Xu Qiongzi He Peng Wei Mengying Ke Shijia Liu Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease Frontiers in Medicine serum metabolomics Crohn's disease biomarker LC-MS metabolite profile |
| title | Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease |
| title_full | Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease |
| title_fullStr | Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease |
| title_full_unstemmed | Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease |
| title_short | Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease |
| title_sort | untargeted serum metabolomics reveals specific metabolite abnormalities in patients with crohn s disease |
| topic | serum metabolomics Crohn's disease biomarker LC-MS metabolite profile |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.814839/full |
| work_keys_str_mv | AT huanhuanliu untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease AT huanhuanliu untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease AT minminxu untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease AT qiongzihe untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease AT pengwei untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease AT mengyingke untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease AT shijialiu untargetedserummetabolomicsrevealsspecificmetaboliteabnormalitiesinpatientswithcrohnsdisease |